Scholarlink

Background <p>The aim of the current study was to evaluate the diagnostic performances of GAAD score, PIVKA-II and alpha-fetoprotein (AFP) for hepatocellular carcinoma (HCC) surveillance in HCC, chronic liver disease (CLD) and healthy controls (HC) subjects from the northeastern Peninsular Malaysia.</p> Methods <p>This was a single-center cross-sectional study. The GAAD value was calculated using the Elecsysâ GAAD calculator. Serum PIVKA-II and AFP levels were measured using the Elecsysâ electrochemiluminescence immunoassay method. Diagnostic performance of these tests were evaluated based on area under the curve (AUC), optimal cutoff levels, sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV).</p> Results <p>Of the 128 enrolled subjects,99 were included (33 HCC, 33 CLD, and 33 HC). GAAD score, PIVKA-II, and AFP levels were significantly higher in patients with HCC than in those with CLD and HC (all <i>p</i> &lt; 0.05). For differentiating HCC from CLD, GAAD at a cutoff of 2.57 demonstrated the highest Se (81.8%) and Sp (72.7%), with an AUC of 0.873 (95% CI 0.791–0.955). PIVKA-II at a cut-off of 28.4&#xa0;ng/mL showed Se and Sp of 75.8% and 69.7%, respectively, with an AUC of 0.842 (95% CI 0.748–0.936). AFP at a cutoff of 20&#xa0;ng/mL demonstrated lower Se (51.5%) but higher Sp (90.9%), with an AUC of 0.834 (95% CI 0.730–0.938). For differentiating HCC from HC, GAAD and PIVKA-II achieved 100% Sp and PPV, whereas AFP maintained 100% Sp but lower Se (51.52%). Overall, GAAD exhibited the best balance of sensitivity and specificity for HCC detection, while PIVKA-II provided complementary diagnostic value due to its high specificity.</p> Conclusion <p>The GAAD score demonstrated superior diagnostic performance compared with both PIVKA-II and AFP in differentiating HCC from CLD and HC subjects, supporting its potential utility in HCC surveillance. In addition, PIVKA-II showed better diagnostic performance than AFP.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diagnostic performance of GAAD, PIVKA-II and AFP in hepatocellular carcinoma, chronic liver disease and healthy population: evidence from a Malaysian cohort

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月25日

查看全文
  • Rabiatul Adawiyyah Mohamad Noor,
  • Nur Karyatee Kassim,
  • Aniza Mohammed Jelani,
  • Lee Yeong Yeh,
  • Mohd Hafizuddin Husin,
  • Wan Muhamad Amir W Ahmad,
  • Nurhanis Syazni Roslan

摘要

Background

The aim of the current study was to evaluate the diagnostic performances of GAAD score, PIVKA-II and alpha-fetoprotein (AFP) for hepatocellular carcinoma (HCC) surveillance in HCC, chronic liver disease (CLD) and healthy controls (HC) subjects from the northeastern Peninsular Malaysia.

Methods

This was a single-center cross-sectional study. The GAAD value was calculated using the Elecsysâ GAAD calculator. Serum PIVKA-II and AFP levels were measured using the Elecsysâ electrochemiluminescence immunoassay method. Diagnostic performance of these tests were evaluated based on area under the curve (AUC), optimal cutoff levels, sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV).

Results

Of the 128 enrolled subjects,99 were included (33 HCC, 33 CLD, and 33 HC). GAAD score, PIVKA-II, and AFP levels were significantly higher in patients with HCC than in those with CLD and HC (all p < 0.05). For differentiating HCC from CLD, GAAD at a cutoff of 2.57 demonstrated the highest Se (81.8%) and Sp (72.7%), with an AUC of 0.873 (95% CI 0.791–0.955). PIVKA-II at a cut-off of 28.4 ng/mL showed Se and Sp of 75.8% and 69.7%, respectively, with an AUC of 0.842 (95% CI 0.748–0.936). AFP at a cutoff of 20 ng/mL demonstrated lower Se (51.5%) but higher Sp (90.9%), with an AUC of 0.834 (95% CI 0.730–0.938). For differentiating HCC from HC, GAAD and PIVKA-II achieved 100% Sp and PPV, whereas AFP maintained 100% Sp but lower Se (51.52%). Overall, GAAD exhibited the best balance of sensitivity and specificity for HCC detection, while PIVKA-II provided complementary diagnostic value due to its high specificity.

Conclusion

The GAAD score demonstrated superior diagnostic performance compared with both PIVKA-II and AFP in differentiating HCC from CLD and HC subjects, supporting its potential utility in HCC surveillance. In addition, PIVKA-II showed better diagnostic performance than AFP.